Image source: FACIT

Facit’s Prospects Fund Fuels Women’s Health and Brain Cancer Therapies for Ontario Patients

Seed-stage commercialization realizes value in the Province’s health research and intellectual property.

September 28, 2022 – FACIT congratulates Ontario-based start-ups Hyivy Health and HDAX Therapeutics as the latest recipients of capital through its Prospects Oncology Fund. Selected among a top-tier pool of applicants, these Ontario-based innovations illustrate excellent potential to benefit patients with cancer.

Former Falcons’ Fortunes pitch competition finalist Hyivy Health is developing a remote patient monitoring, pelvic rehab system for gynecological and colorectal cancer patients and their clinicians. Prospects funding will support a clinical trial currently in protocol development at Grand River Regional Cancer Centre in Kitchener, Ontario. A spin-off from the University of Toronto, HDAX Therapeutics is developing potentially first-in-class, blood-brain barrier permeable HDAC6 selective inhibitors for CNS cancers. Prospects funding will accelerate CTA/IND enabling research and preparation for clinical studies.

Read the original article.

Share this article!

Our website uses cookies to ensure you get the best experience. Learn More